BILLERICA, Mass.– Bruker Corporation is spotlighting a suite of strategic advancements at the 73rd American Society for Mass Spectrometry (ASMS) Conference this week in Baltimore, underscoring its growing leadership in applied markets including therapeutic drug monitoring (TDM), drug of abuse (DoA) analysis, and environmental testing.
A key highlight from Bruker’s Applied Mass Spectrometry (Applied MS) division is the launch of timsMetabo™, a next-generation platform for high-sensitivity small molecule analysis. Designed to tackle emerging needs in environmental monitoring, timsMetabo™ leverages Bruker’s proprietary Trapped Ion Mobility Spectrometry (TIMS) technology, now enhanced with Mobility Range Enhancement (MoRE) and the Athena Ion Processor (AIP). Early studies show timsMetabo™ can detect 40% more low-mass molecules in water samples compared to previous-generation systems, with promising applications in per- and polyfluoroalkyl substances (PFAS) analysis, toxicology, and forensic science.
Also featured at ASMS is Bruker’s recent majority investment in RECIPE, a German-based provider of diagnostic assay kits. The collaboration has resulted in the integration of RECIPE’s ClinMass® and ClinDART® kits with Bruker’s EVOQ® DART-TQ⁺ mass spectrometer, offering high-throughput, chromatography-free workflows tailored for clinical labs. These solutions are particularly geared toward TDM and DoA testing, providing greater ease of use, reduced solvent consumption, and enhanced laboratory efficiency.
The ClinMass® kits, certified under Europe’s IVDR regulation, are designed for triple quadrupole mass spectrometers and are currently being validated for use with Bruker’s systems. Meanwhile, the upcoming ClinDART® kits, still designated for research use only (RUO), aim to support labs looking for robust, cost-effective alternatives for routine compound screening.
“This integration is a significant advancement in therapeutic drug monitoring,” said Dr. Gernot Wolfram, Managing Director at RECIPE. “By combining RECIPE’s assay expertise with Bruker’s instrumentation, we’re enabling labs to adopt faster, more sustainable workflows.”
Bruker executives see the current ASMS conference as a pivotal moment for the company’s Applied MS strategy. “With the launch of timsMetabo™ and our expanded partnership with RECIPE, we’re setting a new benchmark in applied mass spectrometry,” said Jeffrey Zonderman, Senior Vice President of Bruker Applied MS. “These innovations are designed to address urgent analytical challenges—from emerging contaminants to clinical diagnostics—while making mass spectrometry more accessible for routine use.”
Looking ahead, Bruker plans to continue expanding its offerings in areas such as PFAS detection, forensic toxicology, and advanced metabolite analysis, positioning its Applied MS division at the forefront of real-world scientific applications.
